Haematologica, Vol 92, Issue 12, 1719-1720 doi:10.3324/haematol.11516
Copyright © 2007 by Ferrata Storti Foundation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary data
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by von Lilienfeld-Toal, M.
Right arrow Articles by Glasmacher, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by von Lilienfeld-Toal, M.
Right arrow Articles by Glasmacher, A.

Acute Myeloid Leukemia

A randomized comparison of immediate versus delayed application of G-CSF in induction therapy for patients with acute myeloid leukemia unfit for intensive chemotherapy

Marie von Lilienfeld-Toal*,, Corinna Hahn-Ast*, Hartmut Kirchner°, Dimitri Flieger#, Gottfried Dölken@, Axel Glasmacher*

* Medizinische Klinik und Poliklinik I, Universitätsklinikum Bonn, Bonn;
° Klinikum Region Hannover, Siloah, Medizinische Klinik III, Hannover;
# GPR Klinikum, I. Medizinische Klinik, Rüsselsheim;
@ Ernst-Moritz-Arndt-Universität Greifswald, Klinik und Poliklinik für Innere Medizin C, Diagnostikzentrum, Greifswald, Germany

Correspondence: Marie von Lilienfeld-Toal, Medizinische Klinik und Poliklinik I, Universitätsklinikum Bonn, Sigmund-Freud Str. 25, 53105 Bonn. Phone: international +49.22828714003. E-mail: m.lilienfeld.toal{at}uni-bonn.de

We randomized 66 elderly patients with AML unfit for conventional chemotherapy to receive GCSF from d6 or from d12 after induction-chemotherapy with cytarabine/idarubicin. There was no difference in duration of neutropenia (17 days vs. 19 days, p=0.67) or rate of complications. Delayed treatment can reduce the administration of G-CSF without adverse consequences.